UroGen Pharma Ltd. (URGN) Quick Ratio
- Quick ratio · latest quarter: Value 3.18×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.18× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $196.73M ÷ $61.91M ≈ 3.18× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 196.73M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 61.91M USD | Liabilities, Current |
| Cash and equivalents | 79.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 28.84M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 88.76M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 24.59M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $196.73M | $61.91M | $79.13M | $28.84M | $88.76M | $24.59M | 3.18× |
| 2026-03-31 | $195.69M | $50.63M | $109.97M | $30.31M | $55.41M | $20.92M | 3.86× |
| 2025-12-31 | $153.54M | $46.42M | $110.75M | $9.71M | $33.08M | $16.46M | 3.31× |
| 2025-09-30 | $146.74M | $42.24M | $90.04M | $36.99M | $19.70M | $8.34M | 3.47× |
| 2025-06-30 | $176.60M | $47.55M | $92.90M | $64.05M | $19.65M | $7.13M | 3.71× |
| 2025-03-31 | $215.53M | $42.00M | $104.03M | $91.86M | $19.64M | $7.59M | 5.13× |
| 2024-12-31 | $256.99M | $45.95M | $171.99M | $64.70M | $20.30M | $9.23M | 5.59× |
| 2024-09-30 | $272.38M | $32.79M | $124.92M | $124.66M | $22.80M | $7.59M | 8.31× |
| 2024-06-30 | $258.49M | $34.22M | $219.97M | $21.11M | $17.41M | $7.44M | 7.55× |
| 2024-03-31 | $178.20M | $26.34M | $131.44M | $32.61M | $14.16M | $7.24M | 6.77× |
| 2023-12-31 | $152.41M | $31.21M | $95.00M | $41.97M | $15.44M | $5.67M | 4.88× |
| 2023-09-30 | $160.27M | $25.79M | $119.31M | $28.11M | $12.85M | $5.00M | 6.21× |
| 2023-06-30 | $62.81M | $26.77M | $20.13M | $27.17M | $15.51M | $4.99M | 2.35× |
| 2023-03-31 | $77.55M | $25.23M | $36.54M | $28.51M | $12.49M | $5.47M | 3.07× |
| 2022-12-31 | $112.67M | $23.92M | $55.41M | $44.56M | $12.70M | $4.33M | 4.71× |
| 2022-09-30 | $105.34M | $19.00M | $28.69M | $67.22M | $9.43M | $4.86M | 5.54× |
| 2022-06-30 | $123.33M | $18.04M | $80.69M | $31.05M | $11.60M | $5.05M | 6.84× |
| 2022-03-31 | $145.94M | $19.09M | $105.38M | $31.07M | $9.50M | $4.76M | 7.64× |
| 2021-12-31 | $100.86M | $22.38M | $44.36M | $44.78M | $11.72M | $4.83M | 4.51× |
| 2021-09-30 | $113.99M | $19.81M | $55.34M | $50.87M | $7.78M | $3.81M | 5.76× |
| 2021-06-30 | $130.54M | $19.06M | $63.32M | $57.71M | $9.51M | $3.42M | 6.85× |
| 2021-03-31 | $82.21M | $17.00M | $40.49M | $35.42M | $6.30M | $3.33M | 4.83× |
| 2020-12-31 | $109.06M | $21.44M | $52.86M | $49.15M | $7.05M | $1.96M | 5.09× |
| 2020-09-30 | $122.43M | $17.62M | $24.57M | $95.06M | $2.81M | $1.35M | 6.95× |
| 2020-06-30 | $125.53M | $16.42M | $36.35M | $88.77M | $402.00K | $1.13M | 7.64× |
| 2020-03-31 | (m) | $14.21M | $26.47M | $92.62M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $19.48M | $49.69M | $97.39M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $14.09M | $66.15M | $92.05M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $11.84M | $90.42M | $98.74M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $10.28M | $246.69M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $13.46M | $101.32M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $8.97M | $109.48M | (m) | $112.00K | (m) | (m) |
| 2018-06-30 | (m) | $7.95M | $119.11M | (m) | $232.00K | $142.00K | (m) |
| 2018-03-31 | (m) | $5.54M | $127.46M | (m) | $4.00K | $349.00K | (m) |
| 2017-12-31 | (m) | $7.04M | $37.00M | (m) | (m) | $316.00K | (m) |
| 2017-09-30 | (m) | (m) | $79.17M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $77.09M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $18.43M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $3.14M | $21.36M | (m) | $83.00K | $105.00K | (m) |
| 2015-12-31 | (m) | (m) | $17.98M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $3.87M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |